biopharmaceutical company with a
pipeline of selective oral immunology
therapies focused on treating chronic
inflammatory and autoimmune diseases.
Oral Drugs in
small molecule products: lead development
program, vidofludimus calcium (IMU-838), is a
selective DHODH inhibitor; IMU-935 is a
selective inverse agonist of RORγt; and IMU-856
targets the restoration of the intestinal
orally available treatment options with sound
therapeutic efficacy and outstanding safety
and tolerability available to multiple sclerosis
patients, thereby improving the quality
of their lives.
Patients New, Safe
well-tolerated treatment options to patients
suffering from ulcerative colitis and other
gastrointestinal disorders in order to improve
patients’ lives by eliminating the debilitating
side effects of these diseases.
to IBD Patients
Press Releases & Events
“My life’s work revolves around leading companies to successfully develop and commercialize therapeutics that vastly improve the lives of patients suffering from debilitating diseases. Demanding excellence is paramount to success.”
“Beautiful science should be translated into a better life for patients, otherwise, it’s still beautiful, but useless.”
“It is my passion to work with emerging companies to develop ground-breaking technologies. Dedicated, dynamic teams can achieve a lot together when they share mutual respect and empower each other to bring out their best. Or, as the old African proverb says: If you want to go fast, go alone. If you want to go far, work together.”
“Having a positive impact on patients’ lives is the ultimate objective. As a team, we must seize the opportunities to maximize the potential of our programs so that we may also maximize the benefits for patients.“
“My focus is, not only, to review and approve documents but to collaborate with my amazing colleagues in order to make a substantial impact for patients while creating long-term value for our investors and other stakeholders.”
“It is my passion to be a member of an emerging company working with a team of extremely talented people, all focused in the same direction, with the goal of bringing life changing therapies to patients.”
“I am truly honored to work with such a high-powered team on the pursuit of exciting new science. We aim to bring novel and meaningful therapeutic options to doctors and their patients with devastating inflammatory and auto-immune conditions. Each of our drug candidates is potentially best-in-class and targets a product profile designed to improve patients’ lives by combining the convenience of oral delivery, with robust efficacy and patient-friendly tolerability.“
Get in touch.
Immunic Inc, ( Nasdaq: IMUX ) Stock Quote:
Currency in USD. Quote data delayed at least 15 minutes.